Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens
Microbiology · 2026
DOI: 10.1099/mic.0.001663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology, 2026. Verfasst von Vanice Rodrigues Poester und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mycology Laboratory, Post-Graduate Program in Health Science, Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Rio Grande do Sul, B…. Hauptthemen laut MEDLINE: Antifungal Agents, Antimicrobial Peptides, Fungi. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Riptide Bioscience, Vallejo, CA.
Abstract (Originalsprache)
Background
Natural host defence molecules, part of innate immunity and the first line of defence, are evolutionarily conserved. Some pharmaceutical properties undesirable for clinical use led to the rational design of synthetic molecules with constructed peptide arrangements, giving a novel therapeutic avenue. A prior publication showed synthetic peptide RP557 inhibition and killing of fluconazole-sensitive and resistant Candida species isolates, biofilm inhibition, no resistance induction, direct membrane action, negligible mammalian cell toxicity and topical efficacy in a rodent vaginal candidiasis model. These findings highlight the relevance of investigating RP557 activity against other fungal pathogens.
Objective
We evaluated the antifungal spectrum of the RP557 against World Health Organization-listed priority fungal pathogens, including endemic and skin fungal pathogens, both alone and in combination with commercial antifungal drugs.
Methods
The antifungal spectrum was evaluated by broth dilution vs. clinical isolates, and we present 76 MICs (mcg ml −1 ) performed according to M27 or M38 CLSI documents, 35 checkerboard interactions with antifungals and 10 minimum fungicidal determinations.
Results
Overall impression is robust activity vs. chromoblastomycosis and mycetoma species, Cryptococcus neoformans and Trichophyton spp.; broad MIC ranges within most species, least activity vs. Mucorales and Aspergillus spp.; and some promising drug interactions vs. Sporothrix spp. and Candida auris .
Conclusion
Additional efficacy data in vivo is needed. Topical therapy could give local concentrations exceeding MICs, and burn or trauma prophylaxis or treatments are attractive potential targets owing to RP557 panmicrobial properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mycology Laboratory, Post-Graduate Program in Health Science, Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Rio Grande do Sul, Brazil.
- Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
- Colleges of Agriculture and Arts & Sciences, Tuskegee University, Tuskegee, Alabama, USA.
- Div. of Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, California, USA.
Förderung
- Riptide Bioscience, Vallejo, CA
Zitieren
APA
Poester, V. R., Xavier, M. O., Hidalgo, J. E. D., Dos Santos, M. C., Trápaga, M. R., Al-Hatmi, A. M. S., Jaynes, J., & Stevens, D. A. (2026). Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens. Microbiology. https://doi.org/10.1099/mic.0.001663
Vancouver
Poester VR, Xavier MO, Hidalgo JED, Dos Santos MC, Trápaga MR, Al-Hatmi AMS, et al. Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens. Microbiology. 2026. doi:10.1099/mic.0.001663
BibTeX
@article{Poester2026,
author = {Poester, Vanice Rodrigues and Xavier, Melissa Orzechowski and Hidalgo, Jéssica Estefania Dávila and Dos Santos, Mônica Campos and Trápaga, Mariana Rodrigues and Al-Hatmi, Abdullah M S and Jaynes, Jesse and Stevens, David A},
title = {Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens},
journal = {Microbiology},
year = {2026},
doi = {10.1099/mic.0.001663}
}
EUVIMED